Inventor · disambiguated record
Guangdi Wang
Also filed as: WANG GUANGDI
11 granted patents·4 pending applications·10 citations·filing 2011–2022
82Inventor score
Files withXAVIER UNIV OF LOUISIANA8ENDOTARGET INC2THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND2ENHANCEDBIO INC1WANG GUANGDI1
Top patents by PatentIndex Score
15 records- 0174US9353132B2Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancerXAVIER UNIVERSITY OF LOUISIANA·Filed 2013·Granted May 31, 2016·5 cites·41 claims
- 0272US10112962B2Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) groupXAVIER UNIV OF LOUISIANA·Filed 2015·Granted Oct 30, 2018·2 cites·6 claims
- 0370US8962679B2Daidzein analogs as treatment for cancerWANG GUANGDI·Filed 2011·Granted Feb 24, 2015·2 cites·26 claims
- 0467US9669004B2Daidzein analogs as treatment for cancerTHE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND·Filed 2015·Granted Jun 6, 2017·1 cites·24 claims
- 0551US11098053B2Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cellsTHE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND·Filed 2014·Granted Aug 24, 2021·0 cites·10 claims
- 0650US9650369B2Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative diseaseXAVIER UNIV OF LOUISIANA·Filed 2013·Granted May 16, 2017·0 cites·20 claims
- 0748US11708381B2Inhibitors of androgen receptor signalingXAVIER UNIV OF LOUISIANA·Filed 2017·Granted Jul 25, 2023·0 cites·21 claims
- 0845US2023295118A1Compounds and methods for the targeted degradation of cyclin dependent kinasesENHANCEDBIO INC·Filed 2022·Application pending·0 cites
- 0944US11046715B2Boronic derivatives of hydroxamates as anticancer agentsXAVIER UNIV OF LOUISIANA·Filed 2017·Granted Jun 29, 2021·0 cites·19 claims
- 1041US12139492B2Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinaseENDOTARGET INC·Filed 2022·Granted Nov 12, 2024·0 cites·15 claims
- 1141US10017475B2Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancerXAVIER UNIV OF LOUISIANA·Filed 2015·Granted Jul 10, 2018·0 cites·11 claims
- 1239US12109510B2Methods of solvent removal at ambient temperatures—cryovapXAVIER UNIV OF LOUISIANA·Filed 2020·Granted Oct 8, 2024·0 cites·19 claims
- 1339US2019233442A1Selective estrogen receptor down-regulators (serds)XAVIER UNIV OF LOUISIANA·Filed 2017·Application pending·0 cites
- 1439US2022348595A1Compounds and methods for the targeted degradation of estrogen receptorsENDOTARGET INC·Filed 2022·Application pending·0 cites
- 1534US2022041629A1Estrogen receptor targeting antagonistsXAVIER UNIV OF LOUISIANA·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Guangdi Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →